Iterum Therapeutics plc (ITRM) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Iterum Therapeutics plc
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
May 25, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Corey N. Fishman | President, Chief Executive Officer & Director | 1.13M | 1965 |
| Michael W. Dunne | Strategic Advisor & Director | 135,000 | 1960 |
| Judith Matthews | Chief Financial Officer | 677,035 | 1970 |
| Steven I. Aronin | Senior Vice President & Head of Clinical Development | 0 | N/A |
| Kevin Dalton | Senior Director of Legal Affairs & Company Secretary | 0 | N/A |
| Tom Loughman | Senior Vice President of Technical Operations | 0 | N/A |
| Christine R. Coyne | Chief Commercial Officer | 0 | 1970 |
Description
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.
